entertainment -WSS

entertainment

author：explore 2025-10-02 13:13:54 - browse：65556

Red blood cells flow in an artery biotech — coverage from STAT — Adobe

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients.

Among patients with atrial fibrillation, an abnormal heart rhythm that increases the risk of stroke, abelacimab, developed by Anthos Therapeutics, cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto by Janssen Pharmaceuticals.

The treatment, injected monthly, also reduced the risk of major bleeding events by 74% and gastrointestinal bleeding by 93%, according to Phase 2 results presented here Sunday at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： What to expect at HLTH 2023, the health care industry conference

explore

WSS

The creative science of coining drug names

Lawmakers grill UnitedHealth CEO on Change cyberattack

As health system earnings go up, health insurance stocks go down

FDA rejects Alnylam's heart disease treatment over insufficient data

PBM executives asked to testify by House panel

BIO to announce reorganization, senior leaders expected to depart

Wikipedia

entertainment

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Sepsis can kill a child within hours. Here's how hospitals are fighting back

In Memoriam: Notable people who died in 2023

Sana to lay off nearly a third of staff, de

Anesthesiologist group: stop taking Ozempic before surgery

Physician executives need more than on

Drug repurposing or repositioning? The language matters

Bill would stop addiction treatment from triggering child abuse inquiry

leisure time

FDA rejects Alnylam's heart disease treatment over insufficient data

Can gargling with Listerine treat gonorrhea of the mouth?

Why age limits for politicians are a terrible idea

Can gargling with Listerine treat gonorrhea of the mouth?

Novel spinal cord stimulator treats paralysis without surgery

Was Amgen transparent enough on FDA's concern on cancer drug?

focus

explore

leisure time

explore